China Blood Products Industry Report, 2009Research in ChinaOctober 8, 2009 42 Pages - SKU: RIC2554365 |
| The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China’s blood products has soared up and corporate profitability also has increased significantly. China's blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy. The report makes an in-depth analysis of the status quo of China’s blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China’s seven key blood product companies, such as Hualan Biological Engineering Inc. As a key company of blood products R&D and production in China, the revenue of Hualan Biological Engineering Inc achieved RMB475 million in 2008, up 35.32% year-on-year; and the total profit was RMB218 million, a 69.73% YoY rise. Moreover, the current and newly-built plasma collection stations primarily distribute in Guizhou, Guangxi and Chongqing. Up to 2008, it had owned 11 plasma collection stations, and three under construction. It has eased the short supply of plasma via building new plasma collection stations. Hualan Biological Engineering has taken the lead in blood products field in China, in the meantime, it has accessed into vaccine sector actively. It was the first to obtain Influenza A strain on Jun 8, 2009, and it entered the clinical trials on July 22. The monthly output capacity of Influenza A vaccine can reach 7.5 million units, and it would carry the reserves of 4 million units before Sep 15. Besides, it had produced 13 million units of Influenza A vaccine before Oct 1. As is estimated, it can supply 35-40 million units of Influenza A vaccine by the end of 2009. Please Note: PDF E-mail from Publisher purchase option allows up to 10 users and does not allow printing or editing. This functionality will require a Global Site License. |
Related Markets
- Healthcare
- Blood Supply, Tissue Banking, Transplantation
- In Vitro Diagnostics
- Blood Banking & Tissue Typing
Blood Banking & Tissue Typing Reports
- 2012 European Transfusion Diagnostics Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies
- 2012 US Transfusion Diagnostic Testing Market Outlook: Growth Opportunities and Strategies
- 2012 UK Transfusion Diagnostic Testing Market Outlook: Growth Opportunities and Strategies
- 2012 Spain Transfusion Diagnostic Testing Market Outlook: Growth Opportunities and Strategies
- 2012 Japan Transfusion Diagnostic Testing Market Outlook: Growth Opportunities and Strategies
